Influx Health.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Why is Influx Healthtech Ltd falling/rising?

As of 18-Jan, Influx Healthtech Ltd's stock price is rising to 211.35, reflecting a 7.67% increase due to strong relative performance and heightened investor participation. Despite negative returns over the past week, month, and year-to-date, today's performance and increased trading activity may indicate a potential turnaround.

As of 18-Jan, Influx Healthtech Ltd's stock price is rising, currently at 211.35, reflecting a change of 15.05 or 7.67% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 8.78% today, indicating strong relative performance. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 133.62% against the 5-day average, suggesting heightened interest and confidence among investors.<BR><BR>While the stock has shown negative returns over the past week, month, and year-to-date, the current day's performance and increased trading activity may signal a potential turnaround or recovery in sentiment. The stock's current price is also higher than its 100-day and 200-day moving averages, which can be a positive indicator for investors. Overall, the combination of strong performance today and increased investor engagement contributes to the rise in Influx Healthtech Ltd's stock price.

Which are the latest news on Influx Health.?